Burden of illness for metastatic melanoma in Canada, 2011-2013

被引:16
作者
Ernst, D. S. [1 ]
Petrella, T. [2 ]
Joshua, A. M. [3 ]
Hamou, A. [4 ]
Thabane, M. [5 ]
Vantyghem, S. [5 ]
Gwadry-Sridhar, F. [4 ]
机构
[1] London Hlth Sci Ctr, London Reg Canc Program, London, ON, Canada
[2] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Univ Western Ontario, London, ON, Canada
[5] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
关键词
Metastatic melanoma; epidemiology; burden of disease; cancer registries; CUTANEOUS MALIGNANT-MELANOMA; SOCIOECONOMIC-STATUS; PROGNOSTIC-FACTORS; SURVIVAL; TRENDS; DABRAFENIB; THERAPY; PHASE-3; IMMUNOTHERAPY; METAANALYSIS;
D O I
10.3747/co.23.3161
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Detailed epidemiology for patients with advanced metastatic melanoma in Canada is not well characterized. We conducted an analysis of patients with this disease in the province of Ontario, with the aim being to study the presentation, disease characteristics and course, and treatment patterns for malignant melanoma. Methods In this Canadian observational prospective and retrospective study of patients with malignant melanoma, we used data collected in the Canadian Melanoma Research Network (CMRN) Patient Registry. We identified patients who were seen at 1 of 3 cancer treatment centres between April 2011 and 30 April 2013. Patient data from 2011 and 2012 were collected retrospectively using chart records and existing registry data. Starting January 2013, data were collected prospectively. Variables investigated included age, sex, initial stage, histology, mutation type, time to recurrence, sites of metastases, resectability, and previous therapies. Results A cohort of 810 patients with melanoma was identified from the CMRN registry. Mean age was 58.7 years, and most patients were men (60% vs. 40%). Factors affecting survival included unresectable or metastatic melanoma, initial stage at diagnosis, presence of brain metastasis, and BRAF mutation status. The proportion of surviving patients decreased with higher initial disease stages. Conclusions Using registry data, we were able to determine the detailed epidemiology of patients with melanoma in the Canadian province of Ontario, validating the comprehensive and detailed information that can be obtained from registry data.
引用
收藏
页码:E563 / E570
页数:8
相关论文
共 41 条
[1]   Current systemic therapy for metastatic melanoma [J].
Agarwala, Sanjiv S. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (05) :587-595
[2]  
[Anonymous], 2015, CAN CANC STAT 2015
[3]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[4]   From Melanocyte to Metastatic Malignant Melanoma [J].
Bandarchi, Bizhan ;
Ma, Linglei ;
Navab, Roya ;
Seth, Arun ;
Rasty, Golnar .
DERMATOLOGY RESEARCH AND PRACTICE, 2010, 2010
[5]  
Boyle GM, 2011, EXPERT REV ANTICANC, V11, P725, DOI [10.1586/ERA.11.25, 10.1586/era.11.25]
[6]  
Boyle P, 2008, WORLD CANC REPORT 20
[7]  
Cancer Research UK, SKIN CANC MORT STAT
[8]   The epidemiology of skin cancer [J].
Diepgen, TL ;
Mahler, V .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 146 :1-6
[9]   International trends in the incidence of malignant melanoma 1953-2008uare recent generations at higher or lower risk? [J].
Erdmann, Friederike ;
Lortet-Tieulent, Joannie ;
Schuez, Joachim ;
Zeeb, Hajo ;
Greinert, Ruediger ;
Breitbart, Eckhard W. ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (02) :385-400
[10]  
Ferlay J, 2013, INT J CANCER, V1.0